Cancer Gene Therapy Market by Therapy (Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer) - Global Opportunity Analysis and Industry Forecast, 2017-2023

October 2017 | 150 pages | ID: C20C7AA193FEN
Allied Market Research

Abstracts

Gene therapy is an experimental technique that encompasses the replacement of mutated genes with healthy genes. During the treatment of cancer, the genes are replaced to fight against carcinogenic tumor cells. Gene therapy is considered to be an effective treatment for chronic diseases as they cause minimum side effects with maximum efficacy. The global cancer gene therapy market was valued at $289 million in 2016, and is estimated to reach $2,082 million by 2023, registering a CAGR of 32.4% from 2017 to 2023.
The rise in prevalence of cancer, benefits of cancer gene therapy over conventional cancer therapies, and the advancement in this field are the major factors that drive the market growth. In addition, increase in government support, ethical acceptance of gene therapy for cancer treatment, and rise in biotechnological funding encourage the R&D activities for cancer gene therapy and thus fuel the growth of the cancer gene therapy market. However, high cost associated with the treatment and unwanted immune responses are expected to restrain the market growth.
The global cancer gene therapy market is segmented based on therapy, end user, and geography. Based on therapy, it is categorized into gene induced immunotherapy (delivery of cytokines gene and delivery of tumor antigen gene), oncolytic virotherapy (adenovirus, lentivirus, retro virus, adeno associated virus, herpes simplex virus, alpha virus, vaccinia virus, simian virus, and others), and gene transfer (naked plasmid vector, electroporation, sonoportion, magnetofection, and gene gun). Based on geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

• This report offers a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
• The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.
• In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning.
• The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.

KEY PLAYERS PROFILED

• Adaptimmune
• GlaxoSmithKline
• Bluebird bio, Inc.
• Merck
• Celgene
• Shanghai Sunway Biotech
• BioCancell
• Shenzhen SiBiono GeneTech
• SynerGene Therapeutics
• OncoGenex Pharmaceuticals

KEY MARKET SEGMENTS

By Therapy

• Gene Induced Immunotherapy
• Delivery of Cytokines Gene
• Delivery of Tumor Antigen Gene
• Oncolytic Virotherapy
• Adenovirus
• Lentivirus
• Retro Virus
• Adeno Associated Virus
• Herpes Simplex Virus
• Alpha Virus
• Vaccinia Virus
• Simian Virus
• Others
• Gene Transfer
• Naked/Plasmid Vectors
• Electroporation
• Sonoportion
• Magnetofection
• Gene Gun

By End User

• Hospitals
• Diagnostics Centers
• Research Institutes

By Region

• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• UK
• France
• Spain
• Rest of Europe
• Asia-Pacific
• Japan
• China
• Australia
• India
• Rest of Asia-Pacific
• LAMEA
• Brazil
• Republic of South Africa
• Saudi Arabia
• Rest of LAMEA

The other players of the cancer gene therapy market include (companies not profiled in the report):

• Cell Genesys
• Advantagene
• GenVec
• BioCancell
• Celgene and Epeius Biotechnologies
• Introgen Therapeutics
• Ziopharm Oncology
• Shenzhen SiBiono GeneTech
• Genelux Corporation
• Altor Bioscience

Contents

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
  1.4.1. Secondary research
  1.4.2. Primary research
  1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
  3.2.1. Top investment pockets
  3.2.2. Top winning strategies
3.3. REGULATION AND REIMBURSEMENT SCENARIO
3.4. PORTERS FIVE FORCES ANALYSIS
  3.4.1. MARKET DYNAMICS
  3.4.2. Drivers
  3.4.3. Restraints
  3.4.4. Opportunities

CHAPTER 4 CANCER GENE THERAPY MARKET, BY THERAPY

4.1. OVERVIEW
  4.1.1. Market size and forecast
4.2. ONCOLYTIC VIROTHERAPY
  4.2.1. Key market trends
  4.2.2. Growth factors and opportunities
  4.2.3. Market size and forecast
  4.2.4. Adenovirus
  4.2.5. Lentivirus
  4.2.6. Retro virus
  4.2.7. Adeno associated virus
  4.2.8. Herpes simplex virus
  4.2.9. Alpha Virus
  4.2.10. Vaccinia Virus
  4.2.11. Simian Virus
  4.2.12. Others
4.3. GENE TRANSFER
  4.3.1. Key market trends
  4.3.2. Growth factors and opportunities
  4.3.3. Market size and forecast
  4.3.4. Naked plasmid vector
  4.3.5. Electroporation
  4.3.6. Sonoportion
  4.3.7. Magnetofection
  4.3.8. Gene Gun
4.4. GENE-INDUCED IMMUNOTHERAPY
  4.4.1. Key market trends
  4.4.2. Growth factors and opportunities
  4.4.3. Market size and forecast
  4.4.4. Delivery of cytokines gene
  4.4.5. Delivery of tumor antigen gene

CHAPTER 5 CANCER GENE THERAPY MARKET, BY GEOGRAPHY

5.1. OVERVIEW
5.2. NORTH AMERICA
  5.2.1. Key market trends
  5.2.2. Key growth factors and opportunities
  5.2.3. Market size and forecast
    5.2.3.1. U.S. market size and forecast
    5.2.3.2. Canada market size and forecast
    5.2.3.3. Mexico market size and forecast
  5.2.4. North America Cancer gene therapy Market by Therapy
5.3. EUROPE
  5.3.1. Key market trends
  5.3.2. Key growth factors and opportunities
  5.3.3. Market size and forecast
    5.3.3.1. Germany market size and forecast
    5.3.3.2. France market size and forecast
    5.3.3.3. UK market size and forecast
    5.3.3.4. Italy market size and forecast
    5.3.3.5. Spain market size and forecast
    5.3.3.6. Rest of Europe market size and forecast
  5.3.4. Europe Cancer gene therapy Market by Therapy
5.4. ASIA-PACIFIC
  5.4.1. Key market trends
  5.4.2. Key growth factors and opportunities
  5.4.3. Market size and forecast
    5.4.3.1. Japan market size and forecast
    5.4.3.2. China market size and forecast
    5.4.3.3. Australia market size and forecast
    5.4.3.4. India market size and forecast
    5.4.3.5. South Korea market size and forecast
    5.4.3.6. Taiwan market size and forecast
    5.4.3.7. Rest of Asia-Pacific market size and forecast
  5.4.4. Asia-Pacific Cancer gene therapy Market by Therapy
5.5. LAMEA
  5.5.1. Key market trends
  5.5.2. Key growth factors and opportunities
  5.5.3. Market size and forecast
    5.5.3.1. Brazil market size and forecast
    5.5.3.2. Turkey market size and forecast
    5.5.3.3. Saudi Arabia market size and forecast
    5.5.3.4. South Africa market size and forecast
    5.5.3.5. Rest of LAMEA market size and forecast
  5.5.4. LAMEA Cancer gene therapy Market by Therapy

CHAPTER 6 COMPANY PROFILES

6.1. ADAPTIMMUNE
  6.1.1. Operating business segments
  6.1.2. Business performance
  6.1.3. Key strategic moves and developments
6.2. GLAXOSMITHKLINE
  6.2.1. Operating business segments
  6.2.2. Business performance
  6.2.3. Key strategic moves and developments
6.3. BLUEBIRD BIO, INC.
  6.3.1. Operating business segments
  6.3.2. Business performance
  6.3.3. Key strategic moves and developments
6.4. MERCK
  6.4.1. Operating business segments
  6.4.2. Business performance
  6.4.3. Key strategic moves and developments
6.5. CELGENE
  6.5.1. Operating business segments
  6.5.2. Business performance
  6.5.3. Key strategic moves and developments
6.6. SHANGHAI SUNWAY BIOTECH
  6.6.1. Operating business segments
  6.6.2. Business performance
  6.6.3. Key strategic moves and developments
6.7. BIOCANCELL
  6.7.1. Operating business segments
  6.7.2. Business performance
  6.7.3. Key strategic moves and developments
6.8. SHENZHEN SIBIONO GENETECH
  6.8.1. Operating business segments
  6.8.2. Business performance
  6.8.3. Key strategic moves and developments
6.9. SYNERGENE THERAPEUTICS
  6.9.1. Operating business segments
  6.9.2. Business performance
  6.9.3. Key strategic moves and developments
6.10. ONCOGENEX PHARMACEUTICALS
  6.10.1. Operating business segments
  6.10.2. Business performance
  6.10.3. Key strategic moves and developments

List Of Tables

LIST OF TABLES

TABLE 1. GLOBAL CANCER GENE THERAPY MARKET, BY THERAPY, 2016-2023 ($MILLION)
TABLE 2. CANCER GENE THERAPY MARKET FOR GENE INDUCED IMMUNOTHERAPY, BY REGION, 2016-2023 ($MILLION)
TABLE 3. CANCER GENE THERAPY MARKET FOR ONCOLYTIC VIROTHERAPY, BY REGION, 2016-2023 ($MILLION)
TABLE 4. CANCER GENE THERAPY MARKET FOR GENE TRANSFER, BY REGION, 2016-2023 ($MILLION)
TABLE 5. CANCER GENE THERAPY MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 6. NORTH AMERICA CANCER GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 7. NORTH AMERICA CANCER GENE THERAPY MARKET, BY THERAPY, 2016-2023 ($MILLION)
TABLE 8. EUROPE CANCER GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 9. EUROPE CANCER GENE THERAPY MARKET, BY THERAPY, 2016-2023 ($MILLION)
TABLE 10. ASIA-PACIFIC CANCER GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 11. ASIA-PACIFIC CANCER GENE THERAPY MARKET, BY THERAPY, 2016-2023 ($MILLION)
TABLE 12. LAMEA CANCER GENE THERAPY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 13. LAMEA CANCER GENE THERAPY MARKET, BY THERAPY, 2016-2023 ($MILLION)
TABLE 14. ADAPTIMMUNE: COMPANY SNAPSHOT
TABLE 15. ADAPTIMMUNE: OPERATING SEGMENTS
TABLE 16. GLAXOSMITHKLINE: COMPANY SNAPSHOT
TABLE 17. GLAXOSMITHKLINE: OPERATING SEGMENTS
TABLE 18. BLUEBIRD: COMPANY SNAPSHOT
TABLE 19. BLUEBIRD: OPERATING SEGMENTS
TABLE 20. MERCK: COMPANY SNAPSHOT
TABLE 21. MERCK: OPERATING SEGMENTS
TABLE 22. CELGENE: COMPANY SNAPSHOT
TABLE 23. CELGENE: OPERATING SEGMENTS
TABLE 24. SHANGHAI SUNWAY BIOTECH: COMPANY SNAPSHOT
TABLE 25. SHANGHAI SUNWAY BIOTECH: OPERATING SEGMENTS
TABLE 26. BIOCANCELL: COMPANY SNAPSHOT
TABLE 27. BIOCANCELL: OPERATING SEGMENTS
TABLE 28. SHENZHEN SIBIONO GENETECH: COMPANY SNAPSHOT
TABLE 29. SHENZHEN SIBIONO GENETECH: OPERATING SEGMENTS
TABLE 30. SYNERGENE THERAPEUTICS: COMPANY SNAPSHOT
TABLE 31. SYNERGENE THERAPEUTICS: OPERATING SEGMENTS
TABLE 32. ONCOGENEX PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 33. ONCOGENEX PHARMACEUTICALS: OPERATING SEGMENTS

List Of Figures

LIST OF FIGURES

FIGURE 1. SEGMENTATION OF GLOBAL CANCER GENE THERAPY MARKET
FIGURE 2. TOP INVESTMENT POCKETS IN GLOBAL CANCER GENE THERAPY MARKET 2016
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)
FIGURE 4. TOP WINNING STRATEGIES: NATURE AND TYPE (2014-2016)
FIGURE 5. TOP WINNING STRATEGIES: NATURE AND COMPANY (2014-2016)
FIGURE 6. BARGAINING POWER OF BUYERS
FIGURE 7. BARGAINING POWER OF SUPPLIERS
FIGURE 8. THREAT OF NEW ENTRANTS
FIGURE 9. THREAT OF SUBSTITUTION
FIGURE 10. COMPETITIVE RIVALRY
FIGURE 11. RESTRAINTS AND DRIVERS: GLOBAL CANCER GENE THERAPY MARKET
FIGURE 12. GLOBAL CANCER GENE THERAPY MARKET: SEGMENTATION BY TYPE
FIGURE 13. U.S. CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
FIGURE 14. MEXICO CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
FIGURE 15. CANADA CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
FIGURE 16. UK CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
FIGURE 17. FRANCE CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
FIGURE 18. GERMANY CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
FIGURE 19. REST OF EUROPE CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
FIGURE 20. INDIA CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
FIGURE 21. JAPAN CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
FIGURE 22. CHINA CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
FIGURE 23. REST OF ASIA-PACIFIC CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
FIGURE 24. BRAZIL CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
FIGURE 25. SOUTH AFRICA CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
FIGURE 26. SAUDI ARABIA CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)
FIGURE 27. REST OF LAMEA CANCER GENE THERAPY MARKET, 2016-2023 ($MILLION)